Search

Newsletter image

Subscribe to the Newsletter

Join 10k+ people to get notified about new posts, news and tips.

Do not worry we don't spam!

GDPR Compliance

We use cookies to ensure you get the best experience on our website. By continuing to use our site, you accept our use of cookies, Privacy Policy, and Terms of Service.

Hundreds of breast cancer patients to get months of extra life with new NHS drug

Published on December 20, 2022 at 12:01 AM

HUNDREDS of women with breast cancer will get months of extra life thanks to a new NHS drug.

Patients with an incurable type of cancer called HER2-positive will be offered the medicine Enhertu to slow down its progress.

The new drug can halve certain patients’ risk of disease progression or death within the first 18 months of taking it

Around 600 women per year in England are expected to benefit when their cancer comes back after treatment.

Trials found the drug, known as trastuzumab deruxtecan, can halve certain patients’ risk of disease progression or death within the first 18 months of taking it.

It increased the amount of time without tumour growth to an average of 9.9 months, from 5.1 months with standard chemotherapy.

Peter Clark, from NHS England’s Cancer Drugs Fund, said: “This cutting-edge drug will give hundreds of patients with secondary incurable breast cancer hope.

“It will increase the amount of time people have before their cancer gets worse, and allow them to live normal, healthy lives for longer.”;

Chief executive of Breast Cancer Now, Baroness Delyth Morgan, said the approval by the National Institutes for Health and Care Excellence was “fantastic news”;.

Trials of the drug are ongoing to see if it will benefit more groups of patients.

Prev Article

First-time buyer scheme extended by a year to help households with 5% deposits purchase their homes

Next Article

Full list of high street shops and supermarket’s opening hours over Christmas and New Year’s

Related to this topic:

Comments (0):

Be the first to write a comment.

Post Comment

Your email address will not be published. Required fields are marked *